Thrombosis / 2012 / Article
Special Issue

Thrombosis and Aspirin: Clinical Aspect, Aspirin in Cardiology, Aspirin in Neurology, and Pharmacology of Aspirin

View this Special Issue

Editorial | Open Access

Volume 2012 |Article ID 626289 |

Christian Doutremepuich, "Thrombosis and Aspirin: Clinical Aspect, Aspirin in Cardiology, Aspirin in Neurology, and Pharmacology of Aspirin", Thrombosis, vol. 2012, Article ID 626289, 1 page, 2012.

Thrombosis and Aspirin: Clinical Aspect, Aspirin in Cardiology, Aspirin in Neurology, and Pharmacology of Aspirin

Received01 Jul 2012
Accepted01 Jul 2012
Published21 Oct 2012

Acetyl salicylic acid or aspirin is one of the most famous drugs in the world. Aspirin has been increasingly used for prevention of cardiovascular events and is, particularly in recent decades, the most used nonsteroidal anti-inflammatory drug.

Thus, it was necessary to have several contributions to precise the interest and the side effects of aspirin in cardiology, pharmacology, and neurology.

A general review on aspirin pharmacology was made by Espinosa et al. (Western University of Health Sciences, Pomona, CA, USA). This review article helps to understand the role of platelets in primary hemostasis and atherothrombosis, the use of aspirin in the prevention, and treatment of cardiovascular diseases.

In the review article by B. Rocca and G. Petrucci (Catholic University School of Medicine, Rome, Italy), they have detailed the phenomenon of variability in the responsiveness to low-dose aspirin and reported the explanations of this real problem in patients.

The clinical use of aspirin in treatment and prevention of cardiovascular diseases was the subject of the work of Y. Dai and J. Ge (Fudan University, Shanghai, China). In this paper, the authors review the different clinical situations when aspirin is administered.

The use of aspirin for prevention of thrombosis was clearly discussed by G. H. R. Rao and J. Fareed (University of Minnesota, Minneapolis, MN and Loyola University Medical Center, Maywood, IL, USA).

The special work on the role of dermcidin isoform 2 by Ghosh et al. (Calcutta, India) completes the two clinical papers.

The work of Lösche et al. (Jena University Hospital, Jena, Germany) on the problem of the reduction of mortality in critically ill patients also demonstrates the effectiveness of antiplatelet drugs to prevent organ failure.

The three experimental studies from the laboratory of Doutremepuich concern the paradoxical action of aspirin used at different dosages. These different effects can explain the thrombosis observed in clinical practice after aspirin discontinuation. The question could be also: what is the effect of a drug at ultralow dose?

In conclusion, this special issue can represent a “state of art” on aspirin and thrombosis with new hypotheses of work.


Thanks are due to Professors J. Fareed, J. M. Walenga, J.-M. Orgogozo, and M. Lordkipanidzé for their valuable collaboration that enabled the realization of this work. Thanks are also due to D. Duprat, V. Desplat, F. X. Eizayaga, and O. Aguejouf for their technical assistance.

Christian Doutremepuich

Copyright © 2012 Christian Doutremepuich. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.